49ACTIVITIES
1ORGS REPRESENTED
59BILLS
Organizations represented
1Orgs whose LD-2 filings list Annie as an active lobbyist, sorted by activity volume.
Bills they file on
59S. 229630 mentions
S. 65212 mentions
S. 83212 mentions
S. 89112 mentions
S. 93212 mentions
H.R. 94612 mentions
H.R. 126212 mentions
H.R. 149212 mentions
H.R. 221412 mentions
H.R. 394411 mentions
H.R. 412111 mentions
H.R. 421311 mentions
S. 225611 mentions
S. 35511 mentions
S. 141411 mentions
+ 44 more bills referenced in their activities
Topics in Filings
90Policy topics Annie files on across all their LD-2 activities.
One Big Beautiful Bill Act×33
Rural Development×24
Inflation Reduction Act×24
Drug cost and pricing policy×24
Supply chain policy×24
Show all 90 topics (+85 more) ▾
BIOSECURE Act×20
Most Favored Nation×20
Modernizing and Ensuring PBM Accountability×12
Accountability, and Integrity Now and for the Future×12
Vaccine policy×12
Pharmacy Benefit Manager reform×12
Drug importation policy×12
FDA policy×12
Orphan Drug Act×12
Compounding policy×12
Clinical trial policy×12
Issues 340B drug discount program policy×12
Biosimilar approval and reimbursement policy×12
Artificial intelligence policy×12
Part D redesign and policy×12
Part B policy×12
Medicare rebate policy×12
Center for Medicare and Medicaid Innovation×12
Medicaid rebate policy×12
Biopharmaceutical innovation policy×12
International intellectual property and market access policy×12
Pricing and reimbursement policy×12
WTO TRIPS waiver policy×12
China outbound investment policy×12
Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×11
Res. 566: Providing for consideration of the Senate amendment to the bill×11
FDA Modernization×11
Biosimilar Red Tape Elimination Act×11
Energy and Water Development×10
Legislative Branch×10
Military Construction and Veterans Affairs, and Extensions Act, 2026×10
Government funding policy×10
Bipartisan Health Care Act×10
PBM Price Transparency and Accountability Act×10
CLEAR LABELS Act×10
Mikaela Naylon Give Kids a Chance Act×10
PBM Reform×10
HELP Copays Act×10
Most Favored Patients Act×10
FAIR ACT×10
SECURE Rx Act×10
IRA price negotiation expansion policy×10
MAHA Commission Report×10
Make Our Children Healthy Again Competition policy×10
Antimicrobial resistance policy×10
Issues 340B rebate pilot program Patient assistance program policy×10
Biosimilars Access and Affordability Act×10
GENErating cost Reductions for U.S×10
Medicare Against Rising Drugs Costs×10
US-UK Framework Agreement×10
RESTORE Patent Rights Act×2
Give Kids a Chance Act×2
User fee issues×2
Accelerated approval policy×2
Competition policy×2
Antimicrobial resistance×2
Patient assistance program policy×2
Drug shortages policy×2
Insulin policy×2
Medicaid waiver policy×2
Science, and Related Agencies Appropriations Act, 2026×2
Skinny Labels×1
Big Savings Act×1
Affordable Prescriptions for Patients Act×1
Stop STALLING Act×1
Preserve Access to Affordable Generics and Biosimilars Act×1
Interagency Patent Coordination and Improvement Act×1
Bayh-Dole march-in rights policy×1
Patent thicket policy×1
Patent use codes policy×1
AI patent policy×1
Patent eligibility policy×1
Post-grant proceeding policy×1
Patent submission policy×1
Protecting Patients from Deceptive Drug Ads Act×1
Innovation in Pediatric Drugs Act×1
Pandemic preparedness policy×1
Saving Seniors Money on Prescriptions Act×1
Tariff policy×1
Military Construction×1
Expedited Acccess to Biosimilars Act×1
MAPS Act×1
Medication Affordability and Patent Integrity Act×1
Orphan Cures Act×1
Prescription Information Modernization×1
Pulled from the org’s own LD-2 disclosures. See the source filings ↓
Issue mix
LDA general-issue codes weighted by activity count.
Budget/Appropriations12
Health Issues12
Medicare/Medicaid12
Trade (domestic/foreign)12
Copyright/Patent/Trademark1